Kelly D Stone1. 1. Children's Hospital Boston, Department of Pediatrics, Harvard Medical School, Massachusetts, USA. kelly.stone@tch.harvard.edu
Abstract
PURPOSE OF REVIEW: The incidence of atopic diseases, including atopic dermatitis, allergic rhinitis, and asthma, has increased in developed countries over the past several decades. These diseases comprise a large component of general pediatric practice. This review will highlight some of the recent advances in understanding the pathogenesis and natural history of these diseases, as well as the current approaches to the treatment of children with atopic diseases. RECENT FINDINGS: Recent studies have identified multiple risk factors for the development and progression of atopic diseases. As a result, much research is focused on identifying therapies that can be initiated at a young age to prevent disease progression. New treatment options have become available in recent years, such as topical immunomodulators for atopic dermatitis, leukotriene antagonists for seasonal allergic rhinitis, and alpha-immunoglobulin E therapy for asthma. The importance of viewing allergic rhinitis and asthma as disorders of a single airway has been emphasized. Finally, an update on the national asthma guidelines was recently released in an effort to promote optimal asthma care. SUMMARY: This review summarizes many of the recent advances in the diagnosis and treatment of atopic diseases in children. Although not intended to be a comprehensive review of this broad field, it provides a framework for appreciating the complexity of these diseases and for effectively managing them.
PURPOSE OF REVIEW: The incidence of atopic diseases, including atopic dermatitis, allergic rhinitis, and asthma, has increased in developed countries over the past several decades. These diseases comprise a large component of general pediatric practice. This review will highlight some of the recent advances in understanding the pathogenesis and natural history of these diseases, as well as the current approaches to the treatment of children with atopic diseases. RECENT FINDINGS: Recent studies have identified multiple risk factors for the development and progression of atopic diseases. As a result, much research is focused on identifying therapies that can be initiated at a young age to prevent disease progression. New treatment options have become available in recent years, such as topical immunomodulators for atopic dermatitis, leukotriene antagonists for seasonal allergic rhinitis, and alpha-immunoglobulin E therapy for asthma. The importance of viewing allergic rhinitis and asthma as disorders of a single airway has been emphasized. Finally, an update on the national asthma guidelines was recently released in an effort to promote optimal asthma care. SUMMARY: This review summarizes many of the recent advances in the diagnosis and treatment of atopic diseases in children. Although not intended to be a comprehensive review of this broad field, it provides a framework for appreciating the complexity of these diseases and for effectively managing them.
Authors: Dimitrios G Balatsouras; George Koukoutsis; Panayotis Ganelis; Alexandros Fassolis; George S Korres; Antonis Kaberos Journal: Int J Otolaryngol Date: 2011-06-28
Authors: Amy L Shafrir; Marissa C Palmor; Jessica Fourquet; Amy D DiVasta; Leslie V Farland; Allison F Vitonis; Holly R Harris; Marc R Laufer; Daniel W Cramer; Kathryn L Terry; Stacey A Missmer Journal: Am J Reprod Immunol Date: 2021-02-25 Impact factor: 3.777
Authors: Michael A Zulyniak; Russell J de Souza; Mateen Shaikh; Chinthanie Ramasundarahettige; Keith Tam; Natalie Williams; Dipika Desai; Diana L Lefebvre; Milan Gupta; Padmaja Subbarao; Allan B Becker; Piushkumar J Mandhane; Stuart E Turvey; Theo Moraes; Meghan B Azad; Koon K Teo; Malcolm R Sears; Sonia S Anand Journal: PLoS One Date: 2020-05-14 Impact factor: 3.240
Authors: Surendran Mahalingam; Jurgen Schwarze; Ali Zaid; Michael Nissen; Theo Sloots; Sharyn Tauro; James Storer; Rene Alvarez; Ralph A Tripp Journal: Microbes Infect Date: 2005-08-10 Impact factor: 2.700